Investor Alert

May 12, 2022, 7:19 a.m. EDT

Moderna CFO out after two days in the role as former employer Dentsply discloses probe of financial reporting

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Dentsply Sirona Inc. (XRAY)
  • X
    Moderna Inc. (MRNA)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

Moderna Inc. surprised investors Wednesday with the news that its chief financial officer has departed the company just two days after taking up the position, following the disclosure of an internal probe into financial reporting at his former employer.

Jorge Gomez, who became Moderna’s CFO on Monday, has left the biotech after Dentsply Sirona Inc. /zigman2/quotes/204544124/composite XRAY -1.81% disclosed the probe. Before joining Moderna, Gomez had been CFO of Dentsply since 2019.

The maker of dental products and technology said it was late filing its 10-Q quarterly earnings form with the Securities and Exchange because of the investigation.

“The investigation is ongoing, and the company cannot predict the duration or outcome of the investigation,” said the filing. “As a result, the company has not yet finalized its financial statements or its assessment of the impact of the investigation on its historical financial statements or for the financial statements for the three months ended March 31, 2022, and is therefore unable to file the Form 10-Q on a timely basis.”

In a separate filing, the company offered more detail, saying that its audit and finance committees are investigating allegations regarding certain financial matters submitted by former and current employees. The investigation is focused on the company’s use of incentives to sell products to distributors in the third and fourth quarters of 2021 and “whether those incentives were appropriately accounted for and the impact of those sales was adequately disclosed in the company’s periodic reports filed with the SEC.”

See also:   Drug companies are making an accounting change after the SEC cracked down on Biogen

The practice, known as “channel-stuffing,” is a deceptive one used to inflate sales and earnings by deliberately sending more product to distributors than they can reasonably sell. It is usually done at the end of a quarter or year-end reporting period to help the company “make” its numbers and is not allowed under SEC rules.

See also: Moderna’s stock soars 8% after beating revenue, earnings expectations for the quarter

The audit committee is also looking into allegations that current and former members of senior management “directed the use of these incentives and other actions to achieve executive compensation targets in 2021.”

The company has retained outside counsel and a forensic accounting firm. It has also made voluntary disclosures to the SEC and will continue to do so throughout the probe.

Read now: Cigna again adjusts revenue in quarterly earnings in a way that does not conform with SEC rules, experts say

Moderna /zigman2/quotes/205619834/composite MRNA +0.03% said recently retired CFO David Meline will come out of retirement as of May 11 while the company conducts a new CFO search.

Shares fell 3.9% after the news and are down 50% in the year to date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.88% has fallen 16%.

US : U.S.: Nasdaq
$ 35.73
-0.66 -1.81%
Volume: 1.29M
June 30, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$7.84 billion
Rev. per Employee
US : U.S.: Nasdaq
$ 142.85
+0.04 +0.03%
Volume: 5.63M
June 30, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$56.80 billion
Rev. per Employee
-33.45 -0.88%
Volume: 2.68B
June 30, 2022 5:30p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.